Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Journal of Neurology, Neurosurgery, and Psychiatry|May 23, 2014
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacyOrla Tuohy, Lisa Costelloe, Grant Hill-Cawthorne, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 6, 2018
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension studySibyl Wray, Eva Havrdova, David R Snydman, et al.
The Lancet. Neurology|March 15, 2011
Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomesAlasdair J Coles, Edward Fox, Anton Vladic, et al.
Journal of Neurology|June 26, 2020
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223Brian Steingo, Yaser Al Malik, Ann D Bass, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 23, 2012
Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansions of C9ORF72Azza Ismail, Johnathan Cooper-Knock, J Robin Highley, et al.
Therapeutic Advances in Neurological Disorders|May 26, 2021
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trialAlasdair J Coles, Douglas L Arnold, Ann D Bass, et al.
Neurology|September 4, 2016
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MSDouglas L Arnold, Elizabeth Fisher, Vesna V Brinar, et al.
Multiple Sclerosis and Related Disorders|June 5, 2020
Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 yearsJiwon Oh, Anat Achiron, Elisabeth G Celius, et al.
Neurology|August 25, 2017
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findingsAlasdair J Coles, Jeffrey A Cohen, Edward J Fox, et al.
Lancet (London, England)|November 6, 2012
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialAlasdair J Coles, Cary L Twyman, Douglas L Arnold, et al.
Pageof 3